BELANTAMAB MAFODOTIN
Showing 1 - 25 of 55
Corneal Findings in Patients Treated With Belantamab Mafodotin
Not yet recruiting
- Multiple Myeloma
- +2 more
- Belantamab mafodotin
- (no location specified)
Apr 25, 2023
Multiple Myeloma, Multiple Myeloma in Relapse Trial (Belantamab mafodotin, Venetoclax)
Not yet recruiting
- Multiple Myeloma
- Multiple Myeloma in Relapse
- Belantamab mafodotin, Venetoclax
- (no location specified)
May 10, 2023
Plasma Cell Myeloma Trial in Buffalo (Belantamab Mafodotin, Lenalidomide)
Recruiting
- Plasma Cell Myeloma
- Belantamab Mafodotin
- Lenalidomide
-
Buffalo, New YorkRoswell Park Cancer Institute
Dec 5, 2022
Relapsed/Refractory Multiple Myeloma Trial in United States (Belantamab mafodotin)
Not yet recruiting
- Relapsed/Refractory Multiple Myeloma
- Belantamab mafodotin
-
Clayton, North Carolina
- +4 more
May 16, 2023
Multiple Myeloma, Relapse Multiple Myeloma Trial in Chicago (Belantamab mafodotin, Carfilzomib, Pomalidomide)
Not yet recruiting
- Multiple Myeloma
- Relapse Multiple Myeloma
- Belantamab mafodotin
- +3 more
-
Chicago, IllinoisUniversity of Chicago Medicine Comprehensive Cancer Center
Mar 23, 2023
Belantamab Mafodotin Care Patterns in Relapsed and/or Refractory
Not yet recruiting
- Multiple Myeloma
-
Durham, North CarolinaDuke University Medical Center
Aug 8, 2023
Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma Trial in Boston (Isatuximab, Belantamab mafodotin, Pomalidomide)
Not yet recruiting
- Relapsed Cancer
- +2 more
- Isatuximab
- +3 more
-
Boston, Massachusetts
- +1 more
Jun 19, 2023
AL Amyloidosis, Amyloidosis Trial in Stanford, Boston, Rochester (Belantamab mafodotin 2.5 mg/kg (6 weeks), Belantamab mafodotin
Not yet recruiting
- AL Amyloidosis
- Amyloidosis
- Belantamab mafodotin 2.5 mg/kg (6 weeks)
- +4 more
-
Stanford, California
- +3 more
Jul 25, 2022
Multiple Myeloma Trial in United States (Belantamab mafodotin)
Recruiting
- Multiple Myeloma
- Belantamab mafodotin
-
San Francisco, California
- +5 more
Dec 9, 2022
Multiple Myeloma Trial in New Haven (Elotuzumab, Belantamab mafodotin)
Recruiting
- Multiple Myeloma
- Elotuzumab
- Belantamab mafodotin
-
New Haven, ConnecticutYale New Haven Hospital
Aug 15, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Jacksonville (Belantamab Mafodotin, Biospecimen
Not yet recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Belantamab Mafodotin
- +6 more
-
Jacksonville, FloridaMayo Clinic in Florida
Apr 27, 2023
Corneal Toxicity in Patients Treated by Belantamab Mafodotin
Completed
- Myeloma Multiple
- Collection of datas
-
Dijon, France
- +9 more
May 31, 2023
Refractory Multiple Myeloma, Relapse Multiple Myeloma Trial in Milwaukee (Belantamab mafodotin)
Recruiting
- Refractory Multiple Myeloma
- Relapse Multiple Myeloma
- Belantamab mafodotin
-
Milwaukee, WisconsinFroedtert & the Medical College of Wisconsin
Aug 3, 2022
AL Amyloidosis Trial in Worldwide (Belantamab mafodotin)
Recruiting
- AL Amyloidosis
- Belantamab mafodotin
-
Limoges, France
- +5 more
Sep 26, 2022
Myeloma Trial in Philadelphia (Belantamab mafodotin)
Recruiting
- Myeloma
- Belantamab mafodotin
-
Philadelphia, PennsylvaniaAbramson Cancer Center at University of Pennsylvania
Jun 13, 2022
Multiple Myeloma, Tumors, Tumor, Plasma Cell Trial (Belantamab Mafodotin-Blmf, Lenalidomide, Dexamethasone)
Not yet recruiting
- Multiple Myeloma
- +7 more
- Belantamab Mafodotin-Blmf
- +3 more
- (no location specified)
Oct 11, 2022
Multiple Myeloma, Multiple Myeloma in Relapse, Tumors Trial (Belantamab Mafodotin-Blmf, Daratumumab, Pomalidomide)
Not yet recruiting
- Multiple Myeloma
- +8 more
- Belantamab Mafodotin-Blmf
- +3 more
- (no location specified)
Oct 13, 2022
Myeloma Trial in Houston (Belantamab mafodotin)
Recruiting
- Myeloma
- Belantamab mafodotin
-
Houston, TexasM D Anderson Cancer Center
Jul 9, 2022
Multiple Myeloma Trial in Houston (Belantamab mafodotin)
Recruiting
- Multiple Myeloma
- Belantamab mafodotin
-
Houston, TexasM D Anderson Cancer Center
Jan 5, 2023
Plasma Cell Myeloma Trial in Atlanta (Belantamab Mafodotin, Dexamethasone, Pomalidomide)
Recruiting
- Plasma Cell Myeloma
- Belantamab Mafodotin
- +2 more
-
Atlanta, GeorgiaEmory University/Winship Cancer Institute
Jul 21, 2022
Multiple Myeloma Trial in United States (Belantamab Mafodotin, Nirogacestat)
Recruiting
- Multiple Myeloma
- Belantamab Mafodotin
- Nirogacestat
-
Basking Ridge, New Jersey
- +6 more
Oct 5, 2022
Relapsed/Refractory Multiple Myeloma Trial in Baltimore (Belantamab Mafodotin, Cyclophosphamide and Dexamethasone)
Recruiting
- Relapsed/Refractory Multiple Myeloma
- Belantamab Mafodotin, Cyclophosphamide and Dexamethasone
-
Baltimore, MarylandUniversity of Maryland
Jan 24, 2022
Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (biological, drug, other)
Recruiting
- Plasma Cell Myeloma
- +2 more
- Belantamab Mafodotin
- +4 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jun 10, 2022
Relapsed Multiple Myeloma Trial in Spain (Belantamab mafodotin, Carfilzomib, Dexamethasone)
Recruiting
- Relapsed Multiple Myeloma
- Belantamab mafodotin
- +2 more
-
Badalona, Spain
- +14 more
Sep 5, 2022